SecBot SecBot
SECBOTREPLAY Home › Report › IRON

IRON · Disc Medicine announced updated Phase 2 data for DISC-0974 in…

Disc Medicine Inc · PRESS-RELEASE filed Jun 12, 2026 at 08:30 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Jun 12, 2026 at 08:30 ET

Disc Medicine announced updated Phase 2 data for DISC-0974 in myelofibrosis anemia (55% major response in non-transfusion-dependent patients, 64% transfusion independence in low-burden TD) and sustained bitopertin PPIX reductions in EPP at EHA 2026. The company confirmed a Type A meeting with FDA where APOLLO Phase 3 data, due Q4 2026, can serve as basis for a CRL response and potentially support traditional approval. Initial DISC-3405 data in polycythemia vera also expected Q4 2026.

  • Phase 2 RALLY-MF: 55% of nTD patients achieved hemoglobin increase ≥1.5 g/dL for ≥12 weeks (major response)
  • 64% of TD Low and 50% of TD High MF patients achieved transfusion independence over 12-16 weeks
  • 56% of JAK inhibitor-concomitant patients achieved major hematologic response across transfusion groups
  • HELIOS OLE: Sustained PPIX reductions and improved light tolerance with up to 2.5+ years bitopertin exposure

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access